Investor Alert

New York Markets After Hours

The Wall Street Journal Archives | Email alerts

Dec. 3, 2021, 5:22 p.m. EST

Lilly’s COVID-19 antibody drug authorized for use in children

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Eli Lilly & Co. (LLY)

or Cancel Already have a watchlist? Log In

By Joseph Walker

Eli Lilly & Co.’s /zigman2/quotes/200106384/composite LLY +0.91% monoclonal antibody drug has been cleared for emergency use in children under the age of 12, the Food and Drug Administration said on Friday.

The authorization is the first for an antibody drug to treat young children, including newborns, who have tested positive for COVID-19 or been exposed to the virus and who are at high risk of developing severe cases including hospitalization or death.

See also : A new study finds that most COVID-19 boosters strengthen immunity, though there is no winning shot

“Now all patients at high risk of severe COVID-19, including children and newborn babies, have an option for treatment and post-exposure prevention,” said Patrizia Cavazzoni, director of the FDA’s Center for Drug Evaluation and Research.

Children under one year of age who are exposed to the virus that causes Covid-19 may be at particularly high risk of severe disease, said Cavazzoni. She emphasized, however, that antibody drug treatment isn’t a substitute for vaccination, which is authorized for children five years of age and up.

An expanded version of this report appears at WSJ.com .

Top stories from WSJ.com

Antonio Brown, Two Other NFL Players Suspended for Misrepresenting Vaccine Status

A Couple Stored IRA Gold at Home. They Owe the IRS More Than $300,000.

$ 337.65
+3.05 +0.91%
Volume: 2.36M
March 28, 2023 4:03p
P/E Ratio
Dividend Yield
Market Cap
$317.97 billion
Rev. per Employee

Get news alerts on Eli Lilly & Co. — or create your own.
This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.